Seelos rises as FDA accepts clinical trial request for genetic disorder drug

Seelos Therapeutics

08/11/2021 14:22

** Shares of drug developer  SEEL.O  rise 2.3% to $2.26
premarket
    ** Seelos Therapeutics says FDA accepted its application to
conduct clinical trial for its drug candidate, SLS-005, for
treatment of spinocerebellar ataxia  urn:newsml:reuters.com:*:nPn66pjdja
    ** Spinocerebellar ataxia refers to group of hereditary
conditions characterized by degeneration in part of brain
related to movement control with symptoms including
coordination, walking and speech problems
    ** Co says FDA has also granted the program Fast Track
designation; tag is intended to speed up development and review
of new treatments for serious or life-threatening conditions
    ** Co expects to initiate global mid-to-late stage study for
SLS-005 in early 2022
    ** SEEL had risen 39.9% YTD, up to the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))